APA (7th ed.) Citation

JJ, K., G, O., D, K., D, L., AN, H., K, Y., . . . EM, J. (2025). Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43(30), 3325. https://doi.org/10.1200/JCO-25-02195

Chicago Style (17th ed.) Citation

JJ, Knox, et al. "Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 43, no. 30 (2025): 3325. https://doi.org/10.1200/JCO-25-02195.

MLA (9th ed.) Citation

JJ, Knox, et al. "Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 43, no. 30, 2025, p. 3325, https://doi.org/10.1200/JCO-25-02195.